Device type · NGA
Test, Follicle Stimulating Hormone (Fsh), Over The Counter
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
NGA
Clinical Toxicology
Device class
Class I
FDA decisions since 2015
0
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Test, Follicle Stimulating Hormone (Fsh), Over The Counter
- Product code
- NGA
- Device class
- Class I
- Review panel
- Clinical Toxicology
- Regulation
- 21 CFR 862.1300
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for NGA
Latest FDA decisions
No 510(k), De Novo or PMA decisions for this product code since 2015.
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Menopause Test Cassette (Urine)Open, Classified
Changchun Wancheng Bio-Electron Co., Ltd.
Z-1260-2026 · Started Nov 22, 2025 · Posted by FDA Feb 4, 2026
Reason given: Test strips and other tests including for near-patient testing, that require a 510(k) were distributed before they could be legally marketed to U.S. customers; devices may cause false or inaccurate diagnostic result by lay person and lead to inappropriate medical intervention.
Cause as FDA categorized it: No Marketing Application
- Menopause (FSH) 2 TestsOpen, Classified
Z-0744-2026 · Started Nov 3, 2025 · Posted by FDA Dec 1, 2025
Reason given: Distribution without premarket approval/clearance.
Cause as FDA categorized it: No Marketing Application
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.